Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q3 2013 Earnings Presentation

23 slides from Sucampo Pharmaceuticals's earnings presentation, Nov 5, 2013

  1. Slide 1: Third Quarter 2013 Results

    Third Quarter 2013 Results November 5, 2013 e @ SUCAMPO The Science of Innovation

  2. Slide 2: Introductions and Forward-Looking Statements

    ctions and Forward= j Statements Silvia Taylor Senior Vice President, Investor Relations, Public Relations and Corporate Communications ¢ a > SUCAMPO The Science of Innovation

  3. Slide 3: Agenda

    Agenda Introductions and Forward-Looking Statements Silvia Taylor Highlights of the Quarter Ryuji Ueno, M.D., Ph.D., Ph.D. AMITIZA® (lubiprostone) & RESCULA® (unoprostone isopropyl) Commercial Update Sia oe MIEle) Pipeline and R&D Update Taryn Joswick Financial Performance Cary J. Claiborne Closing

  4. Slide 4: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ m

  5. Slide 5: Ryuji Ueno, M.D., Ph.D., Ph.D.

    Ryuji Ueno, M.D., Ph.D., Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer, and Co-founder ¢ 5 > SUCAMPO The Science of Innovation

  6. Slide 6: Commercial Highlights

    Commercial Highlights AMITIZA RESCULA United States Japan Europe United States + Net sales for the + Sales continue to || * Continued to see + Revised first nine months exceed internal increasing sales RESCULA of 2013 YoY forecasts of AMITIZA in commercialization +3.5% to $204.1M , Switzerland for s

  7. Slide 7: Clinical Focus and Stage of Clinical Development

    CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS PRECLINICAL | PHASE 14 PHASE 2 PHASE3 Phase 3 4013 Phase 1b 1014 SUCCESSFULLY COMPLETED [PROJECTED START ONGOING ‘ 7 *Co-developing with R-Tech Ueno, Ltd. $ SUCAMPO ‘The Science of Innovation

  8. Slide 8: Stanley G. Miele

    Stanley G. Miele President, Sucampo Pharma Americas, LLC and SVP, Sales and Marketing $ sucampo The Science of Innovation

  9. Slide 9: AMITIZA U.S.

    AMITIZA U.S Continued AMITIZA YOY Growth * Takeda reported Q3 net sales at $72.5M; 3.5% YoY increase in net sales to $204M through September * Prescriptions up 5.6% Q3 YoY! OIC Opportunity + 40-80% of non-cancer patients on chronic opioids will suffer from oOlc? + Moderate to severely constipated ma

  10. Slide 10: RESCULA commercial update

    See References 4-5 Continued Positive Feedback + RESCULA meets or exceeds prescribers |OP-lowering expectations* + Included in prescribers armamentarium Early Uptake Not Meeting Expectations + RESCULA prescriptions continuing to grow slowly® + Commercialization strategy revised to prioritize efforts

  11. Slide 11: AMITIZA Global Snapshot

    AMITIZA Global Snapshot Japan Sucampo Japan sales up 58.2% to $5.2M Q3 vs. Q2 June disease awareness pilot shown to be effective in motivating patients to ask physicians about AMITIZA* + Abbott to conduct targeted consumer awareness effort with newspaper advertising 2 week limitation removal effecti

  12. Slide 12: Taryn Joswick

    Taryn Joswick Vice President, Clinical Development ¢ 12 ? SUCAMPO The Science of Innovation

  13. Slide 13: AMITIZA Clinical Development & Life Cycle Management

    o Prostone AMITIZA Clinical Development & Life Cycle Management New liquid dosage form + Initiated liquid formulation pivotal trial in CIC in adults October 2013; alternative treatment for patients who | prefer not to take capsules + Takeda funding 100% of development costs NDA filing planned after

  14. Slide 14: Sucampo Prostone Pipeline Key Highlights (cont)

    Sucampo Prostone Pipeline Key Highlights (cont) lon Channel Activators for Lumbar Spinal Steno: Lumbar Spinal Stenosis (LSS) + Degenerative change in lumbar spine; unmet medical need with limited treatment options globally + Treatment phase of P2a, double-blind, placebo- controlled trial of IV ion c

  15. Slide 15: Financial Performance

    al Performance Cary J. Claiborne Chief Financial Officer ¢ 15 3 SUCAMPO The Science of Innovation

  16. Slide 16: Revenues Q3-12 vs Q3-13

    $21.2 $15.5 |. $13.9 $13.6 $5.4 $2.0 $0.7 $- Q3-12 Q3-13 Q3-12 Q3-13 Q3-12 Q3-13 Q3-12 Q3-13 Total Revenues R&D Revenues Product Royalty Product Sales Revenues Revenues *Co-promation, contract and collaboration revenue also are components of revenue. $ sucampo ‘The Science of Innovation

  17. Slide 17: Sales ($M)

    Sales* ($M) $715 $725 Q3-12 03-13 YTD-12 YTD-13 e 3 SUCAMPO *As reported by Takeda for royalty calculation purposes The Science of Innovation

  18. Slide 18: Q3 Income Statement Summary

    Revenue $21.2 $155 36.6% Cost of goods sold $63 0.0 NA Expenses: | | R&D expense $45 $6.6 (20.3% G&A expense $6.4 $7.3 S&M expense $6.0 $43 Loss from operations (61.0) | 61.7) Non-operating expense, net | os) | os Tax benefit (provision) | $2.8 $8) NA GAAP net (income) loss | $1.3 (65.9) NA | EPS —

  19. Slide 19: EPS and Net Income Reconciliation

    EPS GAAP Diluted EPS $ 0.03 | $ 0.10 Difference® 0.06 0.06 Non-GAAP Diluted EPS that exclude RESCULA inventory/samples non-cash write- ae oad off! Net income - GAAP net income? $ 1,201) 8 4,266 Difference 2,716 2,716 Non-GAAP net income that excludes RESCULA inventory/samples non-cash write- 4,007 6

  20. Slide 20: Financial Guidance

    Financial Guidance Full Year 2013 Net Income, excluding special items $3M to $5M. EPS, excluding special items $0.07 to $0.12 2014 Reiterate profitability (specific earnings range to be provided on Q4 earnings call) ¢ 20 3 SUCAMPO ‘The Science of Innovation

  21. Slide 21: Ryuji Ueno, M.D., Ph.D., Ph.D.

    Ryuji Ueno, M.D., Ph.D., Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer, and Co-founder ¢ 24 ? SUCAMPO The Science of Innovation

  22. Slide 22: AMITIZA, RESCULA and Pipeline Milestones

    AMITIZA RESCULA | Lubiprostone | | Lubiprostone | Pipeline | Cobiprostone IV lon Channel Activator v Completed O In Progress a oS (a) ss o ri Obtain approval of OIC sNDA: 1Q 2013 $10M milestone payment upon commercial launch of OIC Pursue strategic alliances; new AMITIZA indications / territories Gr

  23. Slide 23: Sucampo

    ¢ 23 @ SUCAMPO The Science of Innovation

Sucampo Pharmaceuticals — Q3 2013 Earnings Presentation on 6ix